ArticleBlood cancer journal2022

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.

Rami S Komrokji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.